Conflicting COVID-19 results for Roche arthritis drug show more trials needed – Reuters
Larger trials are needed to assess whether Roche’s arthritis drug tocilizumab can cut death rates among the sickest COVID-19 patients, scientists said on Wednesday, after a small study found it was no better than standard care in severe cases.
